---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060269"
form_type: "8-K"
ticker: "MYO"
cik: "0001369290"
company_name: "MYOMO, INC."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T14:14:02.098538+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Myomo Q3 record product revenue $5.0M, up 27% YoY; net loss narrows to $2.0M

## Summary
- Total revenue $5.1M (+28% YoY); product revenue $5.0M (+27%) on 119 units (+37%).
- Net loss $2.0M ($0.06/share) vs $2.8M loss ($0.40/share) in Q3 2022; adjusted EBITDA ($1.7M).
- Received 156 MyoPro orders/authorizations (+20%); pipeline hits 1,046 candidates (+28%).
- CMS reclassifies MyoPro as brace effective Jan 1, 2024; proposed fee rates $31,745 and $62,457.
- First Medicare Part B rental payments received from all four DME MACs; six claims filed.

## SEC filing metadata
- accession: 0000950170-23-060269
- form_type: 8-K
- ticker: MYO
- cik: 0001369290
- company_name: MYOMO, INC.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369290/000095017023060269/0000950170-23-060269-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369290/000095017023060269/myo-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060269
- JSON: https://secwatch.observer/filing/0000950170-23-060269.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060269.txt

## Key facts
- Earnings Releases
  MYOMO, INC. reported the three and nine months ended September 30, 2023 results: revenue Total revenue was $5.1 million, net income Net loss for the third quarter of 2023 was $2.0 million, or $0.06 per share, EPS $0.06 per share.
  - Period: the three and nine months ended September 30, 2023
  - Revenue: Total revenue was $5.1 million
  - Net income: Net loss for the third quarter of 2023 was $2.0 million, or $0.06 per share
  - EPS: $0.06 per share
  - Result: reported results
  source text: --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Myomo Reports Third Quarter 2023 Financial Results Featuring Record Product Revenue and Authorizations Q3 total revenue of $5.1 million, up 28% over the prior year 156 MyoPro orders and insurance authorizations received, including the first payments for five Medicare Part B patients Conference call begins at 4:30
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369290/000095017023060269/0000950170-23-060269-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.